Kuros BiosciencesCSBTF 72 EV-to-EBIT is 154.11 as of Jul. 12, 2026. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $54.78 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 95.93% on this metric.
Kuros Biosciences (OTCPK:CSBTF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kuros Biosciences's Enterprise Value for the quarter that ended in Dec. 2025 was $1,479.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $6.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences EV-to-EBIT Related Terms
Kuros Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's EV-to-EBIT falls into.
Kuros Biosciences's current Enterprise Value is $1,023.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $6.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a EV-to-EBIT of 154.11 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #448 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 95.9%.
Is Kuros Biosciences' EV-to-EBIT too high?
Kuros Biosciences' current EV-to-EBIT is 154.11. The Medical Devices & Instruments industry median EV-to-EBIT is 18.49. Kuros Biosciences' value of 154.11 is 733.5% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #448 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #448 out of 467 companies for EV-to-EBIT. This places Kuros Biosciences in the lower half of its industry. The industry median EV-to-EBIT is 18.49. Kuros Biosciences' value of 154.11 is 733.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.49, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current EV-to-EBIT of 154.11 is 733.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current EV-to-EBIT is 154.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.78, compared to a current price of $25.57 — trading 53.3% below its estimated fair value. The current EV-to-EBIT is 154.11 and 733.5% above the Medical Devices & Instruments industry median of 18.49. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current EV-to-EBIT is 154.11 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $25.57 is trading 53.3% below its estimated GF Value™ of $54.78.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
EV-to-EBIT: 154.11
GF Value™: $54.78 vs. price of $25.57 (53.3% below fair value)
Industry Position: 733.5% above the Medical Devices & Instruments median (#448 of 467)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score
Get the complete analysis for CSBTF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
